<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cardiothorac Surg</journal-id><journal-title>Journal of Cardiothoracic Surgery</journal-title><issn pub-type="epub">1749-8090</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17547746</article-id><article-id pub-id-type="pmc">1892551</article-id><article-id pub-id-type="publisher-id">1749-8090-2-25</article-id><article-id pub-id-type="doi">10.1186/1749-8090-2-25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Study</subject></subj-group></article-categories><title-group><article-title>Morbidity associated with systemic corticosteroid preparation for coronary artery bypass grafting in patients with chronic obstructive pulmonary disease: a case control study</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Starobin</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>starobin@clalit.org.il</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Kramer</surname><given-names>Mordechai Rehuven</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kramerm@clalit.org.il</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Garty</surname><given-names>Moshe</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>garty@clalit.org.il</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Shitirt</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>davids3@clalit.org.il</email></contrib></contrib-group><aff id="I1"><label>1</label>Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><aff id="I2"><label>2</label>Recanati Center for Internal Medicine and Research, Rabin Medical Center, Beilinson Campus, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2007</year></pub-date><volume>2</volume><fpage>25</fpage><lpage>25</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiothoracicsurgery.org/content/2/1/25"></ext-link><history><date date-type="received"><day>10</day><month>11</month><year>2006</year></date><date date-type="accepted"><day>4</day><month>6</month><year>2007</year></date></history><permissions><copyright-statement>Copyright © 2007 Starobin et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Starobin et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3405" xml_f="3415" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3426" xml_f="3561" txt_i="22" txt_f="157">Coronary artery bypass grafting (CABG) is associated with high morbidity in patients with chronic obstructive pulmonary disease (COPD).</offsets></p><p><offsets xml_i="3568" xml_f="3660" txt_i="158" txt_f="250">We examine the effect of preoperative systemic corticosteroids on morbidity in this setting.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3701" xml_f="3708" txt_i="252" txt_f="259">Methods</offsets></title><p><offsets xml_i="3719" xml_f="4245" txt_i="260" txt_f="786">Ninety candidates for elective CABG participated in a prospective, open randomized trial, including 30 patients with COPD who received a single injection of a long-acting corticosteroid, 30 with COPD who received placebo, and 30 without COPD who served as controls. Primary end-points were postoperative pulmonary and nonpulmonary complications. Secondary end-points were length of hospital stay (LOS), ICU stay of less than 24 hours and more than 48 hours, duration of mechanical ventilation, and time to walking and sitting.</offsets></p></sec><sec><title><offsets xml_i="4267" xml_f="4274" txt_i="788" txt_f="795">Results</offsets></title><p><offsets xml_i="4285" xml_f="4548" txt_i="796" txt_f="1059">The rate of pulmonary complications was similar in the two COPD groups and in the COPD patients and controls. The placebo group had more major nonpulmonary complications than the treatment group, but the difference was not statistically significant (26% vs. 17%, </offsets><italic><offsets xml_i="4556" xml_f="4558" txt_i="1059" txt_f="1061">P </offsets></italic><offsets xml_i="4567" xml_f="4708" txt_i="1061" txt_f="1202">= NS). The non-COPD control group had significantly fewer nonpulmonary complications than the COPD patients (treatment+placebo) (33% vs 70%, </offsets><italic><offsets xml_i="4716" xml_f="4718" txt_i="1202" txt_f="1204">P </offsets></italic><offsets xml_i="4727" xml_f="4908" txt_i="1204" txt_f="1385">= 0.014) and a similar rate of pulmonary complications. There was a statistically significant difference between the treated and placebo COPD groups in ICU stay less than 24 hours (</offsets><italic><offsets xml_i="4916" xml_f="4918" txt_i="1385" txt_f="1387">P </offsets></italic><offsets xml_i="4927" xml_f="4989" txt_i="1387" txt_f="1449">≤ 0.001) and more than 48 hours (P = 0.03) and hospital stay (</offsets><italic><offsets xml_i="4997" xml_f="4999" txt_i="1449" txt_f="1451">P </offsets></italic><offsets xml_i="5008" xml_f="5122" txt_i="1451" txt_f="1565">= 0.013). On stepwise analysis, only age and number of coronary grafts were predictors of pulmonary complications.</offsets></p></sec><sec><title><offsets xml_i="5144" xml_f="5154" txt_i="1567" txt_f="1577">Conclusion</offsets></title><p><offsets xml_i="5165" xml_f="5286" txt_i="1578" txt_f="1699">The use of preoperative systemic corticosteroids in patients with COPD undergoing CABG may shorten ICU and hospital stay.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5348" xml_f="5361" txt_i="1708" txt_f="1721">1. Background</offsets></title><p><offsets xml_i="5372" xml_f="5454" txt_i="1722" txt_f="1804">Thoracic surgery is associated with a 10% to 40% rate of pulmonary complications [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5485" xml_f="5486" txt_i="1804" txt_f="1805">1</offsets></xref><offsets xml_i="5493" xml_f="5741" txt_i="1805" txt_f="2047">]. The procedure-related risk factors include high American Society of Anesthesiologists (ASA) class (46% complication rate for class IV vs. 10% for class II) and long duration of surgery (73% for surgery of &gt; 4 hours vs. 38% for &lt; 4 hours) [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5772" xml_f="5773" txt_i="2047" txt_f="2048">2</offsets></xref><offsets xml_i="5780" xml_f="5944" txt_i="2048" txt_f="2212">]; the patient-related risk factors are chronic obstructive pulmonary disease (COPD), asthma, smoking, poor general health status, age above 70 years, and obesity [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5975" xml_f="5976" txt_i="2212" txt_f="2213">1</offsets></xref><offsets xml_i="5983" xml_f="6154" txt_i="2213" txt_f="2384">]. Studies have reported mortality rates ranging from 1% to 50% in patients with COPD and asthma undergoing coronary artery bypass grafting (CABG) or other major surgery [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6185" xml_f="6186" txt_i="2384" txt_f="2385">2</offsets></xref><offsets xml_i="6193" xml_f="6194" txt_i="2385" txt_f="2386">-</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6225" xml_f="6226" txt_i="2386" txt_f="2387">7</offsets></xref><offsets xml_i="6233" xml_f="6502" txt_i="2387" txt_f="2656">]. Patient cessation of cigarette smoking, introduction of vigorous lung-expansion maneuvers, administration of antibiotics if respiratory infection is present, and treatment of airway obstruction have all been suggested as preventive measures in these patient groups [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6533" xml_f="6534" txt_i="2656" txt_f="2657">8</offsets></xref><offsets xml_i="6541" xml_f="6692" txt_i="2657" txt_f="2808">]. Moreover, several researchers have shown that prophylactic treatment with systemic corticosteroids is safe in patients with severe asthma and COPD [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6723" xml_f="6724" txt_i="2808" txt_f="2809">2</offsets></xref><offsets xml_i="6731" xml_f="6732" txt_i="2809" txt_f="2810">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6763" xml_f="6764" txt_i="2810" txt_f="2811">4</offsets></xref><offsets xml_i="6771" xml_f="6772" txt_i="2811" txt_f="2812">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6803" xml_f="6804" txt_i="2812" txt_f="2813">9</offsets></xref><offsets xml_i="6811" xml_f="6884" txt_i="2813" txt_f="2886">] and may help them to tolerate surgery better with fewer complications [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6915" xml_f="6916" txt_i="2886" txt_f="2887">3</offsets></xref><offsets xml_i="6923" xml_f="6924" txt_i="2887" txt_f="2888">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6955" xml_f="6956" txt_i="2888" txt_f="2889">9</offsets></xref><offsets xml_i="6963" xml_f="7032" txt_i="2889" txt_f="2958">]. This is true even for severe corticosteroid-dependent asthmatics [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7063" xml_f="7064" txt_i="2958" txt_f="2959">9</offsets></xref><offsets xml_i="7071" xml_f="7196" txt_i="2959" txt_f="3084">]. However, the efficacy by route of administration (systemic versus inhaled corticosteroids) has not yet been investigated [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7227" xml_f="7228" txt_i="3084" txt_f="3085">1</offsets></xref><offsets xml_i="7235" xml_f="7236" txt_i="3085" txt_f="3086">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7267" xml_f="7268" txt_i="3086" txt_f="3087">4</offsets></xref><offsets xml_i="7275" xml_f="7276" txt_i="3087" txt_f="3088">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7307" xml_f="7308" txt_i="3088" txt_f="3089">8</offsets></xref><offsets xml_i="7315" xml_f="7316" txt_i="3089" txt_f="3090">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7348" xml_f="7350" txt_i="3090" txt_f="3092">12</offsets></xref><offsets xml_i="7357" xml_f="7358" txt_i="3092" txt_f="3093">]</offsets></p><p><offsets xml_i="7365" xml_f="7559" txt_i="3094" txt_f="3288">The aim of the present study was to compare the benefit of preoperative parenteral administration of long-acting corticosteroids (CS) with placebo in patients with COPD undergoing elective CABG.</offsets></p></sec><sec><title><offsets xml_i="7581" xml_f="7604" txt_i="3290" txt_f="3313">2. Patients and methods</offsets></title><sec><title><offsets xml_i="7624" xml_f="7632" txt_i="3314" txt_f="3322">Patients</offsets></title><p><offsets xml_i="7643" xml_f="8056" txt_i="3323" txt_f="3736">The study population consisted of 90 candidates for elective CABG, 60 with COPD and 30 with other disorders, who were treated at the Pulmonary Institute and Department of Thoracic and Cardiovascular Surgery of a tertiary- care hospital between February 1, 2004 and January 31, 2005. The diagnosis of COPD was based on the American Thoracic Society criteria; specifically, forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="8061" xml_f="8062" txt_i="3736" txt_f="3737">1</offsets></sub><offsets xml_i="8068" xml_f="8091" txt_i="3737" txt_f="3760">) less than 70% and FEV</offsets><sub><offsets xml_i="8096" xml_f="8097" txt_i="3760" txt_f="3761">1</offsets></sub><offsets xml_i="8103" xml_f="8168" txt_i="3761" txt_f="3826">/forced vital capacity (FVC) lower than 70% of predicted values [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8200" xml_f="8202" txt_i="3826" txt_f="3828">10</offsets></xref><offsets xml_i="8209" xml_f="8292" txt_i="3828" txt_f="3911">]. Patients were also classified according to the FEV1 based on the ATS statement [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8324" xml_f="8326" txt_i="3911" txt_f="3913">10</offsets></xref><offsets xml_i="8333" xml_f="8746" txt_i="3913" txt_f="4326">]. Both smokers and nonsmokers were included. Patients who had an upper respiratory tract infection or an exacerbation of COPD, patients who were receiving mandatory oral (more than 5 mg) or parenteral corticosteroid treatment for one month before the study, patients who required emergency CABG and patients with asthma were excluded from the study. All the study population used bronchodilators perioperatively.</offsets></p><p><offsets xml_i="8753" xml_f="8880" txt_i="4327" txt_f="4454">The Human Ethics Committee of our hospital approved the study, and all patients signed an informed consent form prior to entry.</offsets></p></sec><sec><title><offsets xml_i="8902" xml_f="8911" txt_i="4456" txt_f="4465">Procedure</offsets></title><p><offsets xml_i="8922" xml_f="9171" txt_i="4466" txt_f="4715">Two to three weeks prior to surgery, the 60 patients with COPD were randomly assigned to receive either a single intramuscular injection of slow-release betamethasone dipropionate 5 mg and rapid-release betamethasone sodium phosphate 2 mg (Diprospan</offsets><sup><offsets xml_i="9176" xml_f="9177" txt_i="4715" txt_f="4716">®</offsets></sup><offsets xml_i="9183" xml_f="9392" txt_i="4716" txt_f="4925">), which is equivalent to 60 mg of prednisone with a duration of action of up to 2–6 weeks (n = 30), or placebo (NaCl 0.9% injection) (n = 30). The remaining 30 patients without COPD served as a control group.</offsets></p><p><offsets xml_i="9399" xml_f="9464" txt_i="4926" txt_f="4991">All other medications remained unchanged during the study period.</offsets></p></sec><sec><title><offsets xml_i="9486" xml_f="9496" txt_i="4993" txt_f="5003">Assessment</offsets></title><p><offsets xml_i="9507" xml_f="10043" txt_i="5004" txt_f="5540">The patients were stratified by grade of left ventricular dysfunction and severity of obstructive lung disease, as determined by the ASA classification [21]. Cardiac and left ventricular assessment was performed by echocardiography with the SONOS-2000 device (Andover, MA, USA). Pulmonary function was assessed with the MedGraphics-Pulmonary Function System 1070 Series 2 (St.- Paul, MN, USA) at the time of randomization, and with a portable spirometer (Vitalograph, London, England) on the day before surgery and the day of discharge.</offsets></p><sec><title><offsets xml_i="10059" xml_f="10080" txt_i="5541" txt_f="5562">2.4. Study end-points</offsets></title><p><offsets xml_i="10091" xml_f="10406" txt_i="5563" txt_f="5878">Primary end-points of the study were postoperative pulmonary complications (atelectasis, pneumonia, pneumothorax, bronchospasm, retained secretion, sustained pleural effusion and respiratory failure) and nonpulmonary complications (arrhythmias, renal failure, heart failure, infections, bleeding, repeated surgery).</offsets></p><p><offsets xml_i="10413" xml_f="10686" txt_i="5879" txt_f="6152">Secondary end-points were length of stay (LOS) in the intensive care unit (ICU), ICU stay less than 24 hours, ICU stay more than 48 hours, duration of mechanical ventilation and chest tube use, LOS in hospital, and intensity of rehabilitation (time to sitting and walking).</offsets></p><p><offsets xml_i="10693" xml_f="10785" txt_i="6153" txt_f="6245">Patients were followed for 2 weeks after discharge by either a clinic visit or a phone call.</offsets></p></sec></sec><sec><title><offsets xml_i="10813" xml_f="10833" txt_i="6248" txt_f="6268">Statistical analysis</offsets></title><p><offsets xml_i="10844" xml_f="11524" txt_i="6269" txt_f="6949">Pearson correlation coefficients (r) and the significance for them (p) were calculated between the variables. To analyze statistically significant differences in categorical variables between the study groups, chi- square test or Fisher's exact test was used, as appropriate. To analyze statistically significant differences in mean continuous parameters between the study groups, analysis of variance with Duncan's multiple comparison option for pairwise comparisons was performed. To predict the number of pulmonary or nonpulmonary complications, a series of stepwise linear regression models was fitted to the data. Odds ratios were calculated from the estimates of the model. </offsets><italic><offsets xml_i="11532" xml_f="11534" txt_i="6949" txt_f="6951">P </offsets></italic><offsets xml_i="11543" xml_f="11619" txt_i="6951" txt_f="7027">values less than or equal to 0.05 were considered statistically significant.</offsets></p></sec></sec><sec><title><offsets xml_i="11647" xml_f="11657" txt_i="7030" txt_f="7040">3. Results</offsets></title><sec><title><offsets xml_i="11677" xml_f="11702" txt_i="7041" txt_f="7066">Baseline demographic data</offsets></title><p><offsets xml_i="11713" xml_f="11774" txt_i="7067" txt_f="7128">All 90 patients completed the 2-week postoperative follow-up.</offsets></p><p><offsets xml_i="11781" xml_f="11799" txt_i="7129" txt_f="7147">As shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="11831" xml_f="11832" txt_i="7147" txt_f="7148">1</offsets></xref><offsets xml_i="11839" xml_f="12006" txt_i="7148" txt_f="7315">, there were no differences among the treatment, placebo, and control groups patients in any of the demographic characteristics. Stratification parameters, namely, FEV</offsets><sub><offsets xml_i="12011" xml_f="12013" txt_i="7315" txt_f="7317">1 </offsets></sub><offsets xml_i="12019" xml_f="12156" txt_i="7317" txt_f="7454">and left ventricular ejection fraction, and stratification class divisions were similar in the treatment and placebo COPD groups (Tables </offsets><xref ref-type="table" rid="T1"><offsets xml_i="12188" xml_f="12189" txt_i="7454" txt_f="7455">1</offsets></xref><offsets xml_i="12196" xml_f="12198" txt_i="7455" txt_f="7457">, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="12230" xml_f="12231" txt_i="7457" txt_f="7458">2</offsets></xref><offsets xml_i="12238" xml_f="12244" txt_i="7458" txt_f="7464">). FEV</offsets><sub><offsets xml_i="12249" xml_f="12251" txt_i="7464" txt_f="7466">1 </offsets></sub><offsets xml_i="12257" xml_f="12329" txt_i="7466" txt_f="7538">was significantly lower in the patients with COPD than in the controls (</offsets><italic><offsets xml_i="12337" xml_f="12339" txt_i="7538" txt_f="7540">P </offsets></italic><offsets xml_i="12348" xml_f="12357" txt_i="7540" txt_f="7549">= 0.001).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="12405" xml_f="12412" txt_i="7550" txt_f="7557">Table 1</offsets></label><caption><p><offsets xml_i="12432" xml_f="12464" txt_i="7557" txt_f="7589">Baseline patient characteristics</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="12554" xml_f="12569" txt_i="7591" txt_f="7606">Diprospan group</offsets><break></break><offsets xml_i="12584" xml_f="12592" txt_i="7606" txt_f="7614">(n = 30)</offsets></td><td align="center"><offsets xml_i="12616" xml_f="12629" txt_i="7615" txt_f="7628">Placebo group</offsets><break></break><offsets xml_i="12644" xml_f="12652" txt_i="7628" txt_f="7636">(n = 30)</offsets></td><td align="center"><offsets xml_i="12676" xml_f="12689" txt_i="7637" txt_f="7650">Control group</offsets><break></break><offsets xml_i="12704" xml_f="12712" txt_i="7650" txt_f="7658">(n = 30)</offsets></td><td align="center"><italic><offsets xml_i="12744" xml_f="12746" txt_i="7659" txt_f="7661">P </offsets></italic><offsets xml_i="12755" xml_f="12761" txt_i="7661" txt_f="7667">value*</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="12807" xml_f="12821" txt_i="7668" txt_f="7682">Male/Female, n</offsets></td><td align="center"><offsets xml_i="12845" xml_f="12849" txt_i="7683" txt_f="7687">26/4</offsets></td><td align="center"><offsets xml_i="12873" xml_f="12877" txt_i="7688" txt_f="7692">24/6</offsets></td><td align="center"><offsets xml_i="12901" xml_f="12905" txt_i="7693" txt_f="7697">27/3</offsets></td><td align="center"><offsets xml_i="12929" xml_f="12931" txt_i="7698" txt_f="7700">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="12962" xml_f="12981" txt_i="7701" txt_f="7720">Age, yr (mean ± SD)</offsets></td><td align="center"><offsets xml_i="13005" xml_f="13016" txt_i="7721" txt_f="7732">67.0 ± 8.98</offsets></td><td align="center"><offsets xml_i="13040" xml_f="13050" txt_i="7733" txt_f="7743">67.7 ± 9.2</offsets></td><td align="center"><offsets xml_i="13074" xml_f="13084" txt_i="7744" txt_f="7754">66.4 ± 9.9</offsets></td><td align="center"><offsets xml_i="13108" xml_f="13110" txt_i="7755" txt_f="7757">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="13141" xml_f="13162" txt_i="7758" txt_f="7779">Smokers/nonsmokers, n</offsets></td><td align="center"><offsets xml_i="13186" xml_f="13190" txt_i="7780" txt_f="7784">24/6</offsets></td><td align="center"><offsets xml_i="13214" xml_f="13218" txt_i="7785" txt_f="7789">26/4</offsets></td><td align="center"><offsets xml_i="13242" xml_f="13247" txt_i="7790" txt_f="7795">20/10</offsets></td><td align="center"><offsets xml_i="13271" xml_f="13273" txt_i="7796" txt_f="7798">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="13304" xml_f="13307" txt_i="7799" txt_f="7802">FEV</offsets><sub><offsets xml_i="13312" xml_f="13313" txt_i="7802" txt_f="7803">1</offsets></sub><offsets xml_i="13319" xml_f="13320" txt_i="7803" txt_f="7804">,</offsets><sup><offsets xml_i="13325" xml_f="13327" txt_i="7804" txt_f="7806">, </offsets></sup><offsets xml_i="13333" xml_f="13334" txt_i="7806" txt_f="7807">%</offsets><break></break><offsets xml_i="13349" xml_f="13360" txt_i="7807" txt_f="7818">(mean ± SD)</offsets></td><td align="center"><offsets xml_i="13384" xml_f="13394" txt_i="7819" txt_f="7829">60.6 ± 9.5</offsets></td><td align="center"><offsets xml_i="13418" xml_f="13428" txt_i="7830" txt_f="7840">62.6 ± 8.0</offsets></td><td align="center"><offsets xml_i="13452" xml_f="13462" txt_i="7841" txt_f="7851">88.6 ± 7.1</offsets></td><td align="center"><offsets xml_i="13486" xml_f="13491" txt_i="7852" txt_f="7857">0.001</offsets></td></tr><tr><td align="left"><offsets xml_i="13522" xml_f="13529" txt_i="7858" txt_f="7865">LVEF, %</offsets><break></break><offsets xml_i="13544" xml_f="13555" txt_i="7865" txt_f="7876">(mean ± SD)</offsets></td><td align="center"><offsets xml_i="13579" xml_f="13590" txt_i="7877" txt_f="7888">46.1 ± 12.4</offsets></td><td align="center"><offsets xml_i="13614" xml_f="13625" txt_i="7889" txt_f="7900">46.1 ± 11.8</offsets></td><td align="center"><offsets xml_i="13649" xml_f="13660" txt_i="7901" txt_f="7912">47.8 ± 10.3</offsets></td><td align="center"><offsets xml_i="13684" xml_f="13686" txt_i="7913" txt_f="7915">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="13717" xml_f="13729" txt_i="7916" txt_f="7928">ASA class, n</offsets></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="13796" xml_f="13797" txt_i="7933" txt_f="7934">2</offsets></td><td align="center"><offsets xml_i="13821" xml_f="13822" txt_i="7935" txt_f="7936">0</offsets></td><td align="center"><offsets xml_i="13846" xml_f="13847" txt_i="7937" txt_f="7938">0</offsets></td><td align="center"><offsets xml_i="13871" xml_f="13872" txt_i="7939" txt_f="7940">2</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="13912" xml_f="13913" txt_i="7942" txt_f="7943">3</offsets></td><td align="center"><offsets xml_i="13937" xml_f="13939" txt_i="7944" txt_f="7946">16</offsets></td><td align="center"><offsets xml_i="13963" xml_f="13965" txt_i="7947" txt_f="7949">21</offsets></td><td align="center"><offsets xml_i="13989" xml_f="13991" txt_i="7950" txt_f="7952">23</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="14031" xml_f="14032" txt_i="7954" txt_f="7955">4</offsets></td><td align="center"><offsets xml_i="14056" xml_f="14058" txt_i="7956" txt_f="7958">14</offsets></td><td align="center"><offsets xml_i="14082" xml_f="14083" txt_i="7959" txt_f="7960">9</offsets></td><td align="center"><offsets xml_i="14107" xml_f="14108" txt_i="7961" txt_f="7962">5</offsets></td><td align="center"><offsets xml_i="14132" xml_f="14136" txt_i="7963" txt_f="7967">0.04</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="14182" xml_f="14236" txt_i="7968" txt_f="8022">*Between COPD groups (treatment+placebo) and controls.</offsets></p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label><offsets xml_i="14315" xml_f="14322" txt_i="8023" txt_f="8030">Table 2</offsets></label><caption><p><offsets xml_i="14342" xml_f="14394" txt_i="8030" txt_f="8082">Distribution of patients with COPD by lung function.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="4"><offsets xml_i="14496" xml_f="14510" txt_i="8084" txt_f="8098">LV Dysfunction</offsets></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="14589" xml_f="14592" txt_i="8101" txt_f="8104">FEV</offsets><sub><offsets xml_i="14597" xml_f="14598" txt_i="8104" txt_f="8105">1</offsets></sub></td><td align="center" colspan="2"><offsets xml_i="14640" xml_f="14673" txt_i="8106" txt_f="8136">Mild LV dysfunction (LVEF&gt;35%)</offsets></td><td align="center" colspan="2"><offsets xml_i="14709" xml_f="14756" txt_i="8137" txt_f="8181">Moderate to severe LV dysfunction (LVEF&lt;34%)</offsets></td></tr><tr><td></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center"><offsets xml_i="14876" xml_f="14891" txt_i="8186" txt_f="8201">Diprospan group</offsets></td><td align="center"><offsets xml_i="14915" xml_f="14928" txt_i="8202" txt_f="8215">Placebo group</offsets></td><td align="center"><offsets xml_i="14952" xml_f="14967" txt_i="8216" txt_f="8231">Diprospan group</offsets></td><td align="center"><offsets xml_i="14991" xml_f="15004" txt_i="8232" txt_f="8245">Placebo group</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="15050" xml_f="15056" txt_i="8246" txt_f="8252">50–70%</offsets></td><td align="center"><offsets xml_i="15080" xml_f="15082" txt_i="8253" txt_f="8255">22</offsets></td><td align="center"><offsets xml_i="15106" xml_f="15108" txt_i="8256" txt_f="8258">23</offsets></td><td align="center"><offsets xml_i="15132" xml_f="15133" txt_i="8259" txt_f="8260">4</offsets></td><td align="center"><offsets xml_i="15157" xml_f="15158" txt_i="8261" txt_f="8262">4</offsets></td></tr><tr><td align="left"><offsets xml_i="15189" xml_f="15195" txt_i="8263" txt_f="8269">35–49%</offsets></td><td align="center"><offsets xml_i="15219" xml_f="15220" txt_i="8270" txt_f="8271">2</offsets></td><td align="center"><offsets xml_i="15244" xml_f="15245" txt_i="8272" txt_f="8273">2</offsets></td><td align="center"><offsets xml_i="15269" xml_f="15270" txt_i="8274" txt_f="8275">1</offsets></td><td align="center"><offsets xml_i="15294" xml_f="15295" txt_i="8276" txt_f="8277">1</offsets></td></tr><tr><td align="left"><offsets xml_i="15326" xml_f="15334" txt_i="8278" txt_f="8283">&lt; 34%</offsets></td><td align="center"><offsets xml_i="15358" xml_f="15359" txt_i="8284" txt_f="8285">1</offsets></td><td align="center"><offsets xml_i="15383" xml_f="15384" txt_i="8286" txt_f="8287">0</offsets></td><td align="center"><offsets xml_i="15408" xml_f="15409" txt_i="8288" txt_f="8289">0</offsets></td><td align="center"><offsets xml_i="15433" xml_f="15434" txt_i="8290" txt_f="8291">0</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="15480" xml_f="15539" txt_i="8292" txt_f="8351">The classification is according to the ATS guidelines [10].</offsets></p><p><offsets xml_i="15546" xml_f="15591" txt_i="8352" txt_f="8397">FEV1 = Forced expiratory volume at one second</offsets></p><p><offsets xml_i="15598" xml_f="15619" txt_i="8398" txt_f="8419">LV = Left ventricular</offsets></p><p><offsets xml_i="15626" xml_f="15667" txt_i="8420" txt_f="8461">LVEF = Left ventricular ejection fraction</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="15705" xml_f="15870" txt_i="8462" txt_f="8627">ASA class was lower in the treatment group than in the placebo group, and significantly higher in the COPD groups (treatment and placebo) than in the control group (</offsets><italic><offsets xml_i="15878" xml_f="15880" txt_i="8627" txt_f="8629">P </offsets></italic><offsets xml_i="15889" xml_f="15897" txt_i="8629" txt_f="8637">= 0.04).</offsets></p></sec><sec><title><offsets xml_i="15919" xml_f="15943" txt_i="8639" txt_f="8663">Changes in lung function</offsets></title><p><offsets xml_i="15954" xml_f="15986" txt_i="8664" txt_f="8696">Lung function (as defined by FEV</offsets><sub><offsets xml_i="15991" xml_f="15992" txt_i="8696" txt_f="8697">1</offsets></sub><offsets xml_i="15998" xml_f="16170" txt_i="8697" txt_f="8869">) was similar in the treatment and placebo groups at all three evaluation time points: randomization, prior to surgery, and after surgery. No significant change in mean FEV</offsets><sub><offsets xml_i="16175" xml_f="16177" txt_i="8869" txt_f="8871">1 </offsets></sub><offsets xml_i="16183" xml_f="16326" txt_i="8871" txt_f="9014">from the time of randomization to prior to surgery was noted in any of the groups. However, after CABG, there was a significant decrease in FEV</offsets><sub><offsets xml_i="16331" xml_f="16333" txt_i="9014" txt_f="9016">1 </offsets></sub><offsets xml_i="16339" xml_f="16360" txt_i="9016" txt_f="9037">in both COPD groups (</offsets><italic><offsets xml_i="16368" xml_f="16370" txt_i="9037" txt_f="9039">P </offsets></italic><offsets xml_i="16379" xml_f="16397" txt_i="9039" txt_f="9057">= 0.001). Mean FEV</offsets><sub><offsets xml_i="16402" xml_f="16404" txt_i="9057" txt_f="9059">1 </offsets></sub><offsets xml_i="16410" xml_f="16588" txt_i="9059" txt_f="9237">in the treatment group was 60.7% at the time of randomization, 61.7% prior to surgery, and 55.3% after CABG; corresponding rates in the placebo group were 62.6%, 64.3% and 54.7%.</offsets></p></sec><sec><title><offsets xml_i="16610" xml_f="16627" txt_i="9239" txt_f="9256">Operative results</offsets></title><p><offsets xml_i="16638" xml_f="16763" txt_i="9257" txt_f="9382">Surgery parameters, including length of operation, bypass time and number of grafts, were similar in all three groups (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="16795" xml_f="16796" txt_i="9382" txt_f="9383">3</offsets></xref><offsets xml_i="16803" xml_f="16805" txt_i="9383" txt_f="9385">).</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="16853" xml_f="16860" txt_i="9386" txt_f="9393">Table 3</offsets></label><caption><p><offsets xml_i="16880" xml_f="16894" txt_i="9393" txt_f="9407">Operative data</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="16984" xml_f="16999" txt_i="9409" txt_f="9424">Diprospan group</offsets></td><td align="center"><offsets xml_i="17023" xml_f="17036" txt_i="9425" txt_f="9438">Placebo group</offsets></td><td align="center"><offsets xml_i="17060" xml_f="17073" txt_i="9439" txt_f="9452">Control group</offsets></td><td align="center"><italic><offsets xml_i="17105" xml_f="17107" txt_i="9453" txt_f="9455">P </offsets></italic><offsets xml_i="17116" xml_f="17122" txt_i="9455" txt_f="9461">value*</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="17168" xml_f="17203" txt_i="9462" txt_f="9497">Duration of surgery, hr (mean ± SD)</offsets></td><td align="center"><offsets xml_i="17227" xml_f="17237" txt_i="9498" txt_f="9508">5.2 ± 0.97</offsets></td><td align="center"><offsets xml_i="17261" xml_f="17270" txt_i="9509" txt_f="9518">5.1 ± 1.1</offsets></td><td align="center"><offsets xml_i="17294" xml_f="17304" txt_i="9519" txt_f="9529">4.75 ± 0.8</offsets></td><td align="center"><offsets xml_i="17328" xml_f="17330" txt_i="9530" txt_f="9532">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="17361" xml_f="17395" txt_i="9533" txt_f="9567">Duration of bypass, hr (mean ± SD)</offsets></td><td align="center"><offsets xml_i="17419" xml_f="17428" txt_i="9568" txt_f="9577">1.7 ± 0.5</offsets></td><td align="center"><offsets xml_i="17452" xml_f="17461" txt_i="9578" txt_f="9587">1.8 ± 0.7</offsets></td><td align="center"><offsets xml_i="17485" xml_f="17494" txt_i="9588" txt_f="9597">1.6 ± 0.4</offsets></td><td align="center"><offsets xml_i="17518" xml_f="17520" txt_i="9598" txt_f="9600">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="17551" xml_f="17576" txt_i="9601" txt_f="9626">No. of grafts (mean ± SD)</offsets></td><td align="center"><offsets xml_i="17600" xml_f="17609" txt_i="9627" txt_f="9636">3.1 ± 0.8</offsets></td><td align="center"><offsets xml_i="17633" xml_f="17642" txt_i="9637" txt_f="9646">3.1 ± 0.9</offsets></td><td align="center"><offsets xml_i="17666" xml_f="17675" txt_i="9647" txt_f="9656">2.9 ± 0.8</offsets></td><td align="center"><offsets xml_i="17699" xml_f="17701" txt_i="9657" txt_f="9659">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="17732" xml_f="17752" txt_i="9660" txt_f="9680">No. of LIMA bypasses</offsets></td><td align="center"><offsets xml_i="17776" xml_f="17778" txt_i="9681" txt_f="9683">24</offsets></td><td align="center"><offsets xml_i="17802" xml_f="17804" txt_i="9684" txt_f="9686">23</offsets></td><td align="center"><offsets xml_i="17828" xml_f="17830" txt_i="9687" txt_f="9689">28</offsets></td><td align="center"><offsets xml_i="17854" xml_f="17856" txt_i="9690" txt_f="9692">NS</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="17902" xml_f="17936" txt_i="9693" txt_f="9727">LIMA- left internal mammary artery</offsets></p><p><offsets xml_i="17943" xml_f="17980" txt_i="9728" txt_f="9765">*Between diprospan and placebo groups</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="18033" xml_f="18051" txt_i="9767" txt_f="9785">Primary end-points</offsets></title><p><offsets xml_i="18062" xml_f="18143" txt_i="9786" txt_f="9867">The rates of pulmonary complications were similar in the two COPD groups (Tables </offsets><xref ref-type="table" rid="T4"><offsets xml_i="18175" xml_f="18176" txt_i="9867" txt_f="9868">4</offsets></xref><offsets xml_i="18183" xml_f="18185" txt_i="9868" txt_f="9870">, </offsets><xref ref-type="table" rid="T5"><offsets xml_i="18217" xml_f="18218" txt_i="9870" txt_f="9871">5</offsets></xref><offsets xml_i="18225" xml_f="18542" txt_i="9871" txt_f="10188">). However, there was significant difference in the rate of pulmonary complications between the COPD groups (treatment+placebo) and the control group. Although more major nonpulmonary complications were observed in the placebo group than in the treatment group, the difference did not reach statistical significance (</offsets><italic><offsets xml_i="18550" xml_f="18552" txt_i="10188" txt_f="10190">P </offsets></italic><offsets xml_i="18561" xml_f="18680" txt_i="10190" txt_f="10309">= 0.8). The patients with COPD (treatment+placebo) had more nonpulmonary complications than the patients without COPD (</offsets><italic><offsets xml_i="18688" xml_f="18690" txt_i="10309" txt_f="10311">P </offsets></italic><offsets xml_i="18699" xml_f="18985" txt_i="10311" txt_f="10597">= 0.014). Specifically, the patients with COPD had a higher rate of atrial tachyarrhythmias (36% treatment group, 26% placebo group) than the controls, and a higher rate of wound infections (20% and 23%, respectively), with or without the need for plastic reconstructive surgery (Table </offsets><xref ref-type="table" rid="T5"><offsets xml_i="19017" xml_f="19018" txt_i="10597" txt_f="10598">5</offsets></xref><offsets xml_i="19025" xml_f="19027" txt_i="10598" txt_f="10600">).</offsets></p><table-wrap position="float" id="T4"><label><offsets xml_i="19075" xml_f="19082" txt_i="10601" txt_f="10608">Table 4</offsets></label><caption><p><offsets xml_i="19102" xml_f="19136" txt_i="10608" txt_f="10642">Operative and postoperative course</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="19226" xml_f="19250" txt_i="10644" txt_f="10668">Diprospan group (n = 30)</offsets></td><td align="center"><offsets xml_i="19274" xml_f="19296" txt_i="10669" txt_f="10691">Placebo group (n = 30)</offsets></td><td align="center"><offsets xml_i="19320" xml_f="19342" txt_i="10692" txt_f="10714">Control group (n = 30)</offsets></td><td align="center"><italic><offsets xml_i="19374" xml_f="19376" txt_i="10715" txt_f="10717">P </offsets></italic><offsets xml_i="19385" xml_f="19391" txt_i="10717" txt_f="10723">value*</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="19437" xml_f="19470" txt_i="10724" txt_f="10757">Pulmonary complications, (%) pts.</offsets></td><td align="center"><offsets xml_i="19494" xml_f="19496" txt_i="10758" txt_f="10760">20</offsets></td><td align="center"><offsets xml_i="19520" xml_f="19522" txt_i="10761" txt_f="10763">20</offsets></td><td align="center"><offsets xml_i="19546" xml_f="19548" txt_i="10764" txt_f="10766">10</offsets></td><td align="center"><offsets xml_i="19572" xml_f="19574" txt_i="10767" txt_f="10769">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="19605" xml_f="19641" txt_i="10770" txt_f="10806">Nonpulmonary complications, (%) pts.</offsets></td><td align="center"><offsets xml_i="19665" xml_f="19667" txt_i="10807" txt_f="10809">70</offsets></td><td align="center"><offsets xml_i="19691" xml_f="19693" txt_i="10810" txt_f="10812">76</offsets></td><td align="center"><offsets xml_i="19717" xml_f="19719" txt_i="10813" txt_f="10815">33</offsets></td><td align="center"><offsets xml_i="19743" xml_f="19745" txt_i="10816" txt_f="10818">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="19776" xml_f="19796" txt_i="10819" txt_f="10839">LOS-ICU, hr (median)</offsets></td><td align="center"><offsets xml_i="19820" xml_f="19822" txt_i="10840" txt_f="10842">93</offsets></td><td align="center"><offsets xml_i="19846" xml_f="19849" txt_i="10843" txt_f="10846">132</offsets></td><td align="center"><offsets xml_i="19873" xml_f="19875" txt_i="10847" txt_f="10849">34</offsets></td><td align="center"><offsets xml_i="19899" xml_f="19901" txt_i="10850" txt_f="10852">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="19932" xml_f="19950" txt_i="10853" txt_f="10868">ICU&lt;24 hours, n</offsets></td><td align="center"><offsets xml_i="19974" xml_f="19976" txt_i="10869" txt_f="10871">19</offsets></td><td align="center"><offsets xml_i="20000" xml_f="20001" txt_i="10872" txt_f="10873">1</offsets></td><td align="center"><offsets xml_i="20025" xml_f="20026" txt_i="10874" txt_f="10875">3</offsets></td><td align="center"><offsets xml_i="20050" xml_f="20059" txt_i="10876" txt_f="10882">&lt;0.001</offsets></td></tr><tr><td align="left"><offsets xml_i="20090" xml_f="20108" txt_i="10883" txt_f="10898">ICU&gt;48 hours, n</offsets></td><td align="center"><offsets xml_i="20132" xml_f="20133" txt_i="10899" txt_f="10900">2</offsets></td><td align="center"><offsets xml_i="20157" xml_f="20158" txt_i="10901" txt_f="10902">8</offsets></td><td align="center"><offsets xml_i="20182" xml_f="20184" txt_i="10903" txt_f="10905">10</offsets></td><td align="center"><offsets xml_i="20208" xml_f="20212" txt_i="10906" txt_f="10910">0.03</offsets></td></tr><tr><td align="left"><offsets xml_i="20243" xml_f="20281" txt_i="10911" txt_f="10949">Mechanical ventilation, hours (median)</offsets></td><td align="center"><offsets xml_i="20305" xml_f="20307" txt_i="10950" txt_f="10952">55</offsets></td><td align="center"><offsets xml_i="20331" xml_f="20333" txt_i="10953" txt_f="10955">80</offsets></td><td align="center"><offsets xml_i="20357" xml_f="20359" txt_i="10956" txt_f="10958">32</offsets></td><td align="center"><offsets xml_i="20383" xml_f="20385" txt_i="10959" txt_f="10961">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="20416" xml_f="20443" txt_i="10962" txt_f="10989">LOS-hospital, days (median)</offsets></td><td align="center"><offsets xml_i="20467" xml_f="20469" txt_i="10990" txt_f="10992">11</offsets></td><td align="center"><offsets xml_i="20493" xml_f="20495" txt_i="10993" txt_f="10995">13</offsets></td><td align="center"><offsets xml_i="20519" xml_f="20520" txt_i="10996" txt_f="10997">8</offsets></td><td align="center"><offsets xml_i="20544" xml_f="20549" txt_i="10998" txt_f="11003">0.013</offsets></td></tr><tr><td align="left"><offsets xml_i="20580" xml_f="20610" txt_i="11004" txt_f="11034">Chest tube time, days (median)</offsets></td><td align="center"><offsets xml_i="20634" xml_f="20635" txt_i="11035" txt_f="11036">3</offsets></td><td align="center"><offsets xml_i="20659" xml_f="20660" txt_i="11037" txt_f="11038">2</offsets></td><td align="center"><offsets xml_i="20684" xml_f="20685" txt_i="11039" txt_f="11040">2</offsets></td><td align="center"><offsets xml_i="20709" xml_f="20711" txt_i="11041" txt_f="11043">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="20742" xml_f="20772" txt_i="11044" txt_f="11074">Time to sitting, days (median)</offsets></td><td align="center"><offsets xml_i="20796" xml_f="20797" txt_i="11075" txt_f="11076">2</offsets></td><td align="center"><offsets xml_i="20821" xml_f="20822" txt_i="11077" txt_f="11078">2</offsets></td><td align="center"><offsets xml_i="20846" xml_f="20847" txt_i="11079" txt_f="11080">2</offsets></td><td align="center"><offsets xml_i="20871" xml_f="20873" txt_i="11081" txt_f="11083">NS</offsets></td></tr><tr><td align="left"><offsets xml_i="20904" xml_f="20934" txt_i="11084" txt_f="11114">Time to walking, days (median)</offsets></td><td align="center"><offsets xml_i="20958" xml_f="20959" txt_i="11115" txt_f="11116">3</offsets></td><td align="center"><offsets xml_i="20983" xml_f="20984" txt_i="11117" txt_f="11118">3</offsets></td><td align="center"><offsets xml_i="21008" xml_f="21009" txt_i="11119" txt_f="11120">3</offsets></td><td align="center"><offsets xml_i="21033" xml_f="21035" txt_i="11121" txt_f="11123">NS</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="21081" xml_f="21128" txt_i="11124" txt_f="11171">ICU = Intensive Care Unit; LOS = length of stay</offsets></p><p><offsets xml_i="21135" xml_f="21173" txt_i="11172" txt_f="11210">*Between Diprospan and placebo groups.</offsets></p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label><offsets xml_i="21252" xml_f="21259" txt_i="11211" txt_f="11218">Table 5</offsets></label><caption><p><offsets xml_i="21279" xml_f="21306" txt_i="11218" txt_f="11245">Postoperative complications</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="21385" xml_f="21398" txt_i="11246" txt_f="11259">Complications</offsets></td><td align="center"><offsets xml_i="21422" xml_f="21437" txt_i="11260" txt_f="11275">Diprospan group</offsets></td><td align="center"><offsets xml_i="21461" xml_f="21474" txt_i="11276" txt_f="11289">Placebo group</offsets></td><td align="center"><offsets xml_i="21498" xml_f="21511" txt_i="11290" txt_f="11303">Control group</offsets></td><td align="center"><italic><offsets xml_i="21543" xml_f="21545" txt_i="11304" txt_f="11306">P </offsets></italic><offsets xml_i="21554" xml_f="21560" txt_i="11306" txt_f="11312">value*</offsets></td><td align="center"><italic><offsets xml_i="21592" xml_f="21594" txt_i="11313" txt_f="11315">P </offsets></italic><offsets xml_i="21603" xml_f="21610" txt_i="11315" txt_f="11322">value*?</offsets></td></tr></thead><tbody><tr><td align="left"><italic><offsets xml_i="21664" xml_f="21673" txt_i="11323" txt_f="11332">Pulmonary</offsets></italic></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="21758" xml_f="21771" txt_i="11338" txt_f="11351">-Bronchospasm</offsets></td><td align="center"><offsets xml_i="21795" xml_f="21796" txt_i="11352" txt_f="11353">2</offsets></td><td align="center"><offsets xml_i="21820" xml_f="21821" txt_i="11354" txt_f="11355">3</offsets></td><td align="center"><offsets xml_i="21845" xml_f="21846" txt_i="11356" txt_f="11357">1</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="21895" xml_f="21905" txt_i="11360" txt_f="11370">-Pneumonia</offsets></td><td align="center"><offsets xml_i="21929" xml_f="21930" txt_i="11371" txt_f="11372">1</offsets></td><td align="center"><offsets xml_i="21954" xml_f="21955" txt_i="11373" txt_f="11374">1</offsets></td><td align="center"><offsets xml_i="21979" xml_f="21980" txt_i="11375" txt_f="11376">1</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="22029" xml_f="22041" txt_i="11379" txt_f="11391">-Atelectasis</offsets></td><td align="center"><offsets xml_i="22065" xml_f="22066" txt_i="11392" txt_f="11393">1</offsets></td><td align="center"><offsets xml_i="22090" xml_f="22091" txt_i="11394" txt_f="11395">0</offsets></td><td align="center"><offsets xml_i="22115" xml_f="22116" txt_i="11396" txt_f="11397">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="22165" xml_f="22182" txt_i="11400" txt_f="11417">-Pleural effusion</offsets></td><td align="center"><offsets xml_i="22206" xml_f="22207" txt_i="11418" txt_f="11419">1</offsets></td><td align="center"><offsets xml_i="22231" xml_f="22232" txt_i="11420" txt_f="11421">0</offsets></td><td align="center"><offsets xml_i="22256" xml_f="22257" txt_i="11422" txt_f="11423">2</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="22306" xml_f="22319" txt_i="11426" txt_f="11439">-Pneumothorax</offsets></td><td align="center"><offsets xml_i="22343" xml_f="22344" txt_i="11440" txt_f="11441">0</offsets></td><td align="center"><offsets xml_i="22368" xml_f="22369" txt_i="11442" txt_f="11443">1</offsets></td><td align="center"><offsets xml_i="22393" xml_f="22394" txt_i="11444" txt_f="11445">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="22443" xml_f="22463" txt_i="11448" txt_f="11468">-Respiratory failure</offsets></td><td align="center"><offsets xml_i="22487" xml_f="22488" txt_i="11469" txt_f="11470">1</offsets></td><td align="center"><offsets xml_i="22512" xml_f="22513" txt_i="11471" txt_f="11472">1</offsets></td><td align="center"><offsets xml_i="22537" xml_f="22538" txt_i="11473" txt_f="11474">1</offsets></td><td></td><td></td></tr><tr><td align="left"><italic><offsets xml_i="22595" xml_f="22610" txt_i="11477" txt_f="11492">Total pulmonary</offsets></italic></td><td align="center"><offsets xml_i="22643" xml_f="22649" txt_i="11493" txt_f="11499">6(20%)</offsets></td><td align="center"><offsets xml_i="22673" xml_f="22680" txt_i="11500" txt_f="11507">6 (20%)</offsets></td><td align="center"><offsets xml_i="22704" xml_f="22711" txt_i="11508" txt_f="11515">5 (10%)</offsets></td><td align="center"><offsets xml_i="22735" xml_f="22739" txt_i="11516" txt_f="11520">0.56</offsets></td><td align="center"><offsets xml_i="22763" xml_f="22767" txt_i="11521" txt_f="11525">0.02</offsets></td></tr><tr><td align="left"><italic><offsets xml_i="22806" xml_f="22818" txt_i="11526" txt_f="11538">Nonpulmonary</offsets></italic></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><underline><offsets xml_i="22914" xml_f="22919" txt_i="11544" txt_f="11549">Major</offsets></underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23007" xml_f="23024" txt_i="11555" txt_f="11572">- Wound infection</offsets></td><td align="center"><offsets xml_i="23048" xml_f="23049" txt_i="11573" txt_f="11574">2</offsets></td><td align="center"><offsets xml_i="23073" xml_f="23074" txt_i="11575" txt_f="11576">4</offsets></td><td align="center"><offsets xml_i="23098" xml_f="23099" txt_i="11577" txt_f="11578">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23148" xml_f="23169" txt_i="11581" txt_f="11602">- Acute renal failure</offsets></td><td align="center"><offsets xml_i="23193" xml_f="23194" txt_i="11603" txt_f="11604">1</offsets></td><td align="center"><offsets xml_i="23218" xml_f="23219" txt_i="11605" txt_f="11606">0</offsets></td><td align="center"><offsets xml_i="23243" xml_f="23244" txt_i="11607" txt_f="11608">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23293" xml_f="23301" txt_i="11611" txt_f="11619">- Stroke</offsets></td><td align="center"><offsets xml_i="23325" xml_f="23326" txt_i="11620" txt_f="11621">1</offsets></td><td align="center"><offsets xml_i="23350" xml_f="23351" txt_i="11622" txt_f="11623">2</offsets></td><td align="center"><offsets xml_i="23375" xml_f="23376" txt_i="11624" txt_f="11625">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23425" xml_f="23433" txt_i="11628" txt_f="11636">- Sepsis</offsets></td><td align="center"><offsets xml_i="23457" xml_f="23458" txt_i="11637" txt_f="11638">0</offsets></td><td align="center"><offsets xml_i="23482" xml_f="23483" txt_i="11639" txt_f="11640">1</offsets></td><td align="center"><offsets xml_i="23507" xml_f="23508" txt_i="11641" txt_f="11642">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23557" xml_f="23569" txt_i="11645" txt_f="11657">- Re-surgery</offsets></td><td align="center"><offsets xml_i="23593" xml_f="23594" txt_i="11658" txt_f="11659">1</offsets></td><td align="center"><offsets xml_i="23618" xml_f="23619" txt_i="11660" txt_f="11661">1</offsets></td><td align="center"><offsets xml_i="23643" xml_f="23644" txt_i="11662" txt_f="11663">2</offsets></td><td></td><td></td></tr><tr><td align="left"><italic><offsets xml_i="23701" xml_f="23712" txt_i="11666" txt_f="11677">Total major</offsets></italic></td><td align="center"><offsets xml_i="23745" xml_f="23752" txt_i="11678" txt_f="11685">5 (17%)</offsets></td><td align="center"><offsets xml_i="23776" xml_f="23783" txt_i="11686" txt_f="11693">8 (26%)</offsets></td><td align="center"><offsets xml_i="23807" xml_f="23813" txt_i="11694" txt_f="11700">2 (7%)</offsets></td><td align="center"><offsets xml_i="23837" xml_f="23840" txt_i="11701" txt_f="11704">0.8</offsets></td><td align="center"><offsets xml_i="23864" xml_f="23868" txt_i="11705" txt_f="11709">0.03</offsets></td></tr><tr><td align="left"><underline><offsets xml_i="23910" xml_f="23915" txt_i="11710" txt_f="11715">Minor</offsets></underline></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24003" xml_f="24011" txt_i="11721" txt_f="11729">- Atrial</offsets></td><td align="center"><offsets xml_i="24035" xml_f="24037" txt_i="11730" txt_f="11732">11</offsets></td><td align="center"><offsets xml_i="24061" xml_f="24062" txt_i="11733" txt_f="11734">8</offsets></td><td align="center"><offsets xml_i="24086" xml_f="24087" txt_i="11735" txt_f="11736">1</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24136" xml_f="24154" txt_i="11739" txt_f="11757">tachyarrhythmias -</offsets></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24230" xml_f="24247" txt_i="11763" txt_f="11780">Superficial wound</offsets></td><td align="center"><offsets xml_i="24271" xml_f="24272" txt_i="11781" txt_f="11782">4</offsets></td><td align="center"><offsets xml_i="24296" xml_f="24297" txt_i="11783" txt_f="11784">3</offsets></td><td align="center"><offsets xml_i="24321" xml_f="24322" txt_i="11785" txt_f="11786">4</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24371" xml_f="24381" txt_i="11789" txt_f="11799"> infection</offsets></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24457" xml_f="24477" txt_i="11805" txt_f="11825">- Transient oliguria</offsets></td><td align="center"><offsets xml_i="24501" xml_f="24502" txt_i="11826" txt_f="11827">1</offsets></td><td align="center"><offsets xml_i="24526" xml_f="24527" txt_i="11828" txt_f="11829">2</offsets></td><td align="center"><offsets xml_i="24551" xml_f="24552" txt_i="11830" txt_f="11831">3</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24601" xml_f="24626" txt_i="11834" txt_f="11859">- Urinary tract infection</offsets></td><td align="center"><offsets xml_i="24650" xml_f="24651" txt_i="11860" txt_f="11861">0</offsets></td><td align="center"><offsets xml_i="24675" xml_f="24676" txt_i="11862" txt_f="11863">1</offsets></td><td align="center"><offsets xml_i="24700" xml_f="24701" txt_i="11864" txt_f="11865">0</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="24750" xml_f="24762" txt_i="11868" txt_f="11880">- Acute gout</offsets></td><td align="center"><offsets xml_i="24786" xml_f="24787" txt_i="11881" txt_f="11882">0</offsets></td><td align="center"><offsets xml_i="24811" xml_f="24812" txt_i="11883" txt_f="11884">1</offsets></td><td align="center"><offsets xml_i="24836" xml_f="24837" txt_i="11885" txt_f="11886">0</offsets></td><td></td><td></td></tr><tr><td align="left"><italic><offsets xml_i="24894" xml_f="24905" txt_i="11889" txt_f="11900">Total minor</offsets></italic></td><td align="center"><offsets xml_i="24938" xml_f="24946" txt_i="11901" txt_f="11909">16 (53%)</offsets></td><td align="center"><offsets xml_i="24970" xml_f="24978" txt_i="11910" txt_f="11918">15 (50%)</offsets></td><td align="center"><offsets xml_i="25002" xml_f="25009" txt_i="11919" txt_f="11926">8 (27%)</offsets></td><td align="center"><offsets xml_i="25033" xml_f="25036" txt_i="11927" txt_f="11930">0.1</offsets></td><td align="center"><offsets xml_i="25060" xml_f="25064" txt_i="11931" txt_f="11935">0.01</offsets></td></tr><tr><td align="left"><italic><offsets xml_i="25103" xml_f="25121" txt_i="11936" txt_f="11954">Total nonpulmonary</offsets></italic></td><td align="center"><offsets xml_i="25154" xml_f="25162" txt_i="11955" txt_f="11963">21 (70%)</offsets></td><td align="center"><offsets xml_i="25186" xml_f="25194" txt_i="11964" txt_f="11972">23 (76%)</offsets></td><td align="center"><offsets xml_i="25218" xml_f="25226" txt_i="11973" txt_f="11981">10 (33%)</offsets></td><td align="center"><offsets xml_i="25250" xml_f="25254" txt_i="11982" txt_f="11986">0.79</offsets></td><td align="center"><offsets xml_i="25278" xml_f="25282" txt_i="11987" txt_f="11991">0.01</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="25328" xml_f="25367" txt_i="11992" txt_f="12031">* Between Diprospan and placebo groups.</offsets></p><p><offsets xml_i="25374" xml_f="25409" txt_i="12032" txt_f="12067">** Between Control and COPD groups.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="25462" xml_f="25482" txt_i="12069" txt_f="12089">Secondary end-points</offsets></title><p><offsets xml_i="25493" xml_f="25574" txt_i="12090" txt_f="12171">There was a statistically significant difference in ICU stay less than 24 hours (</offsets><italic><offsets xml_i="25582" xml_f="25584" txt_i="12171" txt_f="12173">P </offsets></italic><offsets xml_i="25593" xml_f="25628" txt_i="12173" txt_f="12205">&lt; 0.001) or more than 48 hours (</offsets><italic><offsets xml_i="25636" xml_f="25638" txt_i="12205" txt_f="12207">P </offsets></italic><offsets xml_i="25647" xml_f="25703" txt_i="12207" txt_f="12263">= 0.03) between the treatment and placebo groups (Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="25735" xml_f="25736" txt_i="12263" txt_f="12264">4</offsets></xref><offsets xml_i="25743" xml_f="25825" txt_i="12264" txt_f="12346">). The treatment group also had a shorter LOS in hospital than the placebo group (</offsets><italic><offsets xml_i="25833" xml_f="25835" txt_i="12346" txt_f="12348">P </offsets></italic><offsets xml_i="25844" xml_f="26125" txt_i="12348" txt_f="12629">= 0.013). The duration of mechanical ventilation was longer in the placebo than the treatment group, but this difference did not reach statistical significance. There were no between-group differences in chest tube time or postoperative rehabilitation (sitting and walking) (Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="26157" xml_f="26158" txt_i="12629" txt_f="12630">4</offsets></xref><offsets xml_i="26165" xml_f="26167" txt_i="12630" txt_f="12632">).</offsets></p></sec><sec><title><offsets xml_i="26189" xml_f="26209" txt_i="12634" txt_f="12654">Correlation analysis</offsets></title><p><offsets xml_i="26220" xml_f="26309" txt_i="12655" txt_f="12744">The nonpulmonary complications and length of ICU stay correlated significantly with age (</offsets><italic><offsets xml_i="26317" xml_f="26319" txt_i="12744" txt_f="12746">P </offsets></italic><offsets xml_i="26328" xml_f="26493" txt_i="12746" txt_f="12911">= 0.04), but not with left ventricular dysfunction grade, length of surgery, or bypass time. The duration of mechanical ventilation correlated significantly with FEV</offsets><sub><offsets xml_i="26498" xml_f="26500" txt_i="12911" txt_f="12913">1 </offsets></sub><offsets xml_i="26506" xml_f="26507" txt_i="12913" txt_f="12914">(</offsets><italic><offsets xml_i="26515" xml_f="26517" txt_i="12914" txt_f="12916">P </offsets></italic><offsets xml_i="26526" xml_f="26628" txt_i="12916" txt_f="13018">= 0.009) and no significantly with age, left ventricular function, length of surgery, and bypass time.</offsets></p><p><offsets xml_i="26635" xml_f="26770" txt_i="13019" txt_f="13154">Correlation analysis showed that the risks of occurrence of both pulmonary and nonpulmonary complications increased with age, lower FEV</offsets><sub><offsets xml_i="26775" xml_f="26776" txt_i="13154" txt_f="13155">1</offsets></sub><offsets xml_i="26782" xml_f="26862" txt_i="13155" txt_f="13235">, longer ICU stay, longer mechanical ventilation, and prolonged hospitalization.</offsets></p><p><offsets xml_i="26869" xml_f="27131" txt_i="13236" txt_f="13498">On stepwise regression analysis, age and number of coronary grafts were the most significant predictors of pulmonary complications. Specifically, pulmonary complications increased by 0.6% for each year of age and more than twofold for every additional new graft.</offsets></p></sec></sec><sec><title><offsets xml_i="27159" xml_f="27172" txt_i="13501" txt_f="13514">4. Discussion</offsets></title><p><offsets xml_i="27183" xml_f="27353" txt_i="13515" txt_f="13685">The results of our study are consistent with previous reports showing that in patients with COPD, the risk of postoperative pulmonary complications rises with older age [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="27384" xml_f="27385" txt_i="13685" txt_f="13686">1</offsets></xref><offsets xml_i="27392" xml_f="27404" txt_i="13686" txt_f="13698">], lower FEV</offsets><sub><offsets xml_i="27409" xml_f="27411" txt_i="13698" txt_f="13700">1 </offsets></sub><offsets xml_i="27417" xml_f="27418" txt_i="13700" txt_f="13701">[</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="27449" xml_f="27450" txt_i="13701" txt_f="13702">2</offsets></xref><offsets xml_i="27457" xml_f="27496" txt_i="13702" txt_f="13741">], and more complex coronary grafting [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="27527" xml_f="27528" txt_i="13741" txt_f="13742">1</offsets></xref><offsets xml_i="27535" xml_f="27594" txt_i="13742" txt_f="13801">]. ASA class and duration of operation are also important [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="27626" xml_f="27628" txt_i="13801" txt_f="13803">13</offsets></xref><offsets xml_i="27635" xml_f="27636" txt_i="13803" txt_f="13804">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="27668" xml_f="27670" txt_i="13804" txt_f="13806">14</offsets></xref><offsets xml_i="27677" xml_f="27893" txt_i="13806" txt_f="14022">]. In patients who are older than 70 years or who have peripheral vascular disease, insulin-dependent diabetes mellitus, congestive heart failure, anemia, or COPD, the postoperative mortality ranges from 11% to 19% [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="27924" xml_f="27925" txt_i="14022" txt_f="14023">6</offsets></xref><offsets xml_i="27932" xml_f="28058" txt_i="14023" txt_f="14149">]. In patients with COPD, the highest pulmonary complication rates occur after CABG and major abdominal procedures (50%–60%) [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="28089" xml_f="28090" txt_i="14149" txt_f="14150">5</offsets></xref><offsets xml_i="28097" xml_f="28098" txt_i="14150" txt_f="14151">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="28130" xml_f="28132" txt_i="14151" txt_f="14153">15</offsets></xref><offsets xml_i="28139" xml_f="28141" txt_i="14153" txt_f="14155">].</offsets></p><p><offsets xml_i="28148" xml_f="28344" txt_i="14156" txt_f="14352">The most significant post-CABG complications have been found to be heart failure with shock, arrhythmias, pulmonary infection and atelectasis, stroke, renal failure, and surgical wound infection [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="28375" xml_f="28376" txt_i="14352" txt_f="14353">6</offsets></xref><offsets xml_i="28383" xml_f="28384" txt_i="14353" txt_f="14354">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="28416" xml_f="28418" txt_i="14354" txt_f="14356">16</offsets></xref><offsets xml_i="28425" xml_f="28750" txt_i="14356" txt_f="14681">]. Accordingly, in the present study, the rates of nonpulmonary complications, particularly atrial tachyarrhythmias and wound infections, were quite high in the patients with COPD. One possible explanation is the poor general health status of this patient population. In our series, 23 of the 60 patients were in ASA class 4.</offsets></p><p><offsets xml_i="28757" xml_f="28775" txt_i="14682" txt_f="14700">Sauerland et al. [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="28807" xml_f="28809" txt_i="14700" txt_f="14702">17</offsets></xref><offsets xml_i="28816" xml_f="29321" txt_i="14702" txt_f="15207">] conducted a risk benefit analysis using a meta-analysis, to compare complication rates and clinical advantages associated with the use of a single preoperative high dose of steroid in surgical patients. They found that perioperative single-shot administration of high dose methylprednisolone is not associated with a significant increase in the incidence of adverse effects. In patients with multiple fractures, limited evidence suggests promising benefits of glucocorticoids on pulmonary complications.</offsets></p><p><offsets xml_i="29328" xml_f="29575" txt_i="15208" txt_f="15455">Michalopoulos et al. assessed the impact of history of mild-moderate COPD on outcome in patients undergoing elective CABG surgery. [18] They found that the patients with COPD have similar morbidy and mortality rates comparable to those of control.</offsets></p><p><offsets xml_i="29582" xml_f="30273" txt_i="15456" txt_f="16147">Regarding the benefit of preoperative steroid administration in preventing postoperative complications in patients with COPD – for which previous data are lacking – we failed to find any difference in the prevalence of pulmonary complications between the patients given Diprospan and the placebo group. The treated group had fewer nonpulmonary complications than the placebo group, but the difference did not reach statistical significance. Furthermore, the patients with COPD (either pretreated or not) had a significantly higher rate of nonpulmonary complications than the control patients without COPD who underwent elective CABG. The latter findings are consistent with earlier studies [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="30304" xml_f="30305" txt_i="16147" txt_f="16148">1</offsets></xref><offsets xml_i="30312" xml_f="30313" txt_i="16148" txt_f="16149">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="30344" xml_f="30345" txt_i="16149" txt_f="16150">2</offsets></xref><offsets xml_i="30352" xml_f="30353" txt_i="16150" txt_f="16151">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="30384" xml_f="30385" txt_i="16151" txt_f="16152">6</offsets></xref><offsets xml_i="30392" xml_f="30393" txt_i="16152" txt_f="16153">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="30425" xml_f="30427" txt_i="16153" txt_f="16155">10</offsets></xref><offsets xml_i="30434" xml_f="30435" txt_i="16155" txt_f="16156">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="30467" xml_f="30469" txt_i="16156" txt_f="16158">12</offsets></xref><offsets xml_i="30476" xml_f="30672" txt_i="16158" txt_f="16354">] At the same time, we found that the patients receiving steroids had both a significantly shorter ICU stay and significantly shorter hospital stay than the patients with CPD who received placebo.</offsets></p><p><xref ref-type="bibr" rid="B2"><offsets xml_i="30710" xml_f="30711" txt_i="16355" txt_f="16356">2</offsets></xref><offsets xml_i="30718" xml_f="30719" txt_i="16356" txt_f="16357">-</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="30750" xml_f="30751" txt_i="16357" txt_f="16358">5</offsets></xref><offsets xml_i="30758" xml_f="30856" txt_i="16358" txt_f="16456">] These effects may shorten the ICU-LOS and the mechanical ventilation period. In addition, table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="30888" xml_f="30889" txt_i="16456" txt_f="16457">2</offsets></xref><offsets xml_i="30896" xml_f="31177" txt_i="16457" txt_f="16738"> presented higher ICU-LOS and mechanical ventilation period in the control group. Partial explanation could be the lack of systemic steroids in this group. Therefore, we believe that inhaled steroids can not give the entire anti-inflammatory effect that systemic steroids achieved.</offsets></p><p><offsets xml_i="31184" xml_f="31459" txt_i="16739" txt_f="17014">Our study has some limitations. First, the small number of patients may have led to a lower statistical power of the variables. Second, the patients were followed for only 2 weeks after hospital discharge. Nevertheless, preoperative steroids proved to be an important adjunct</offsets></p><p><offsets xml_i="31466" xml_f="31858" txt_i="17015" txt_f="17407">In conclusion, patients with COPD are at higher risk for post-CABG complications, particularly nonpulmonary ones, such as atrial tachyarrhythmias and wound infection. The administration of preoperative systemic steroids may be of benefit in reducing their postoperative ICU and hospital stay. Larger-scale studies that include more patients with severe COPD are needed to confirm our results.</offsets></p></sec><sec><title><offsets xml_i="31880" xml_f="31899" txt_i="17409" txt_f="17428">Competing interests</offsets></title><p><offsets xml_i="31910" xml_f="31970" txt_i="17429" txt_f="17489">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="31992" xml_f="32014" txt_i="17491" txt_f="17513">Authors' contributions</offsets></title><p><offsets xml_i="32025" xml_f="32086" txt_i="17514" txt_f="17575">Daniele Starobin: Design, aquired data, design, drafted paper</offsets></p><p><offsets xml_i="32093" xml_f="32136" txt_i="17576" txt_f="17619">David Shitrit: drafted paper, analyzed data</offsets></p><p><offsets xml_i="32143" xml_f="32185" txt_i="17620" txt_f="17662">Moshe Garty: Conceived, interpretated data</offsets></p><p><offsets xml_i="32192" xml_f="32248" txt_i="17663" txt_f="17719">Mordechai R Kramer: Approval of final version, conceived</offsets></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smetana</surname><given-names>GW</given-names></name></person-group><article-title>Preoperative pulmonary evaluation</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">10089188</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199903253401207</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Lawrence</surname><given-names>VA</given-names></name><name><surname>Theroux</surname><given-names>JF</given-names></name><name><surname>Tuley</surname><given-names>MR</given-names></name></person-group><article-title>Operative risk in patients with severe obstructive pulmonary disease</article-title><source>Arch Intern Med</source><year>1992</year><volume>152</volume><fpage>967</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">1580723</pub-id><pub-id pub-id-type="doi">10.1001/archinte.152.5.967</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pien</surname><given-names>LC</given-names></name><name><surname>Grammer</surname><given-names>LC</given-names></name><name><surname>Patterson</surname><given-names>R</given-names></name></person-group><article-title>Minimal complications in a surgical population with severe asthma receiving prophylactic corticosteroids</article-title><source>J Allergy Clin Immunol</source><year>1988</year><volume>82</volume><fpage>696</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">3171010</pub-id><pub-id pub-id-type="doi">10.1016/0091-6749(88)90985-2</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kabalin</surname><given-names>CS</given-names></name><name><surname>Yarnold</surname><given-names>PL</given-names></name><name><surname>Grammer</surname><given-names>LC</given-names></name></person-group><article-title>Low complication rate of corticosteroid-treated asthmatics undergoing surgical procedures</article-title><source>Arch Intern Med</source><year>1995</year><volume>155</volume><fpage>1379</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">7794086</pub-id><pub-id pub-id-type="doi">10.1001/archinte.155.13.1379</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paone</surname><given-names>G</given-names></name><name><surname>Higgins</surname><given-names>RSD</given-names></name><name><surname>Havstad</surname><given-names>SL</given-names></name><name><surname>Silberman</surname><given-names>AN</given-names></name></person-group><article-title>Does age limit the effectiveness of clinical pathways after coronary artery bypass graft surgery?</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>41</fpage><lpage>II</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarhan</surname><given-names>S</given-names></name><name><surname>Moffit</surname><given-names>EA</given-names></name><name><surname>Sessler</surname><given-names>AD</given-names></name><name><surname>Douglas</surname><given-names>WW</given-names></name><name><surname>Taylor</surname><given-names>WF</given-names></name></person-group><article-title>Risk of anesthesia and surgery in patients with chronic bronchitis and chronic obstructive pulmonary disease</article-title><source>Surgery</source><year>1973</year><volume>74</volume><fpage>720</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">4742756</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>HD</given-names></name><name><surname>Stevens</surname><given-names>PM</given-names></name><name><surname>Adaniya</surname><given-names>R</given-names></name></person-group><article-title>Preoperative pulmonary function and complications after cardiovascular surgery</article-title><source>Chest</source><year>1979</year><volume>76</volume><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">456050</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>MCV</given-names></name></person-group><article-title>Preoperative pulmonary evaluation</article-title><source>Arch Intern Med</source><year>1988</year><volume>148</volume><fpage>2120</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">3052344</pub-id><pub-id pub-id-type="doi">10.1001/archinte.148.10.2120</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Patterson</surname><given-names>R</given-names></name></person-group><article-title>Surgery in corticosteroid-dependent asthmatics</article-title><source>J Allergy Clin Immunol</source><year>1974</year><volume>53</volume><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">4827905</pub-id><pub-id pub-id-type="doi">10.1016/0091-6749(74)90118-3</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><article-title>Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and Asthma</article-title><source>Am Rev Resp Dis</source><year>1987</year><volume>136</volume><fpage>225</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">3605835</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurki</surname><given-names>TSO</given-names></name><name><surname>Kataya</surname><given-names>M</given-names></name></person-group><article-title>Preoperative prediction of postoperative morbidity in coronary artery bypass grafting</article-title><source>Ann Thorac Surg</source><year>1996</year><volume>61</volume><fpage>1740</fpage><lpage>1745</lpage><pub-id pub-id-type="pmid">8651777</pub-id><pub-id pub-id-type="doi">10.1016/0003-4975(96)00142-7</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name></person-group><article-title>Perioperative management of patient with chronic obstructive pulmonary disease</article-title><source>Int Anesth Clin</source><year>1988</year><volume>26</volume><fpage>134</fpage><lpage>142</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>SK</given-names></name><name><surname>Faling</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>BDT</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><article-title>Predicting complications after pulmonary resection</article-title><source>Chest</source><year>1993</year><volume>104</volume><fpage>694</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">8365278</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gracey</surname><given-names>DR</given-names></name><name><surname>Divertie</surname><given-names>MB</given-names></name><name><surname>Didier</surname><given-names>EP</given-names></name></person-group><article-title>Preoperative pulmonary preparation of patients with chronic obstructive pulmonary disease</article-title><source>Chest</source><year>1979</year><volume>76</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">456049</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magovern</surname><given-names>JA</given-names></name><name><surname>Sakert</surname><given-names>T</given-names></name><name><surname>Magovern</surname><given-names>GJ</given-names></name></person-group><article-title>A model that predicts morbidity and mortality after coronary artery bypass graft surgery</article-title><source>J Am Coll Cardiol</source><year>1996</year><volume>28</volume><fpage>1147</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">8890808</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(96)00310-5</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hallett</surname><given-names>JW</given-names></name><name><surname>Bower</surname><given-names>TC</given-names></name><name><surname>Cherry</surname><given-names>KJ</given-names></name><name><surname>Gloviczki</surname><given-names>P</given-names></name><name><surname>Joyce</surname><given-names>JW</given-names></name><name><surname>pairolero</surname><given-names>PC</given-names></name></person-group><article-title>Selection and preparation of high-risk patients for repair of abdominal aortic aneurysms</article-title><source>Mayo Clin Proc</source><year>1994</year><volume>69</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">8035633</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauerland</surname><given-names>S</given-names></name><name><surname>Nagelschmidt</surname><given-names>M</given-names></name><name><surname>Mallmann</surname><given-names>P</given-names></name><name><surname>Neugebauer</surname><given-names>EA</given-names></name></person-group><article-title>Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review</article-title><source>Drug Saf</source><year>2000</year><volume>23</volume><fpage>449</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11085349</pub-id><pub-id pub-id-type="doi">10.2165/00002018-200023050-00007</pub-id></citation></ref></ref-list></back></article>